Capture SBIR Biotech Trust via Failure Analysis Media
- Organization
- National Science Foundation SBIR Program
- Sector
- SBIR-funded biotech companies facing commercialization failure risks
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF SBIR Phase I award provides AICONIC BIOSCIENCES with $305,000 non-dilutive funding for gene therapy platform development but creates structural commercial gaps between their $350M revenue projection and the grant's 18-month, vendor-constrained scope.
Market catalyst
90% of SBIR-funded biotechs fail to commercialize, creating massive anxiety among current awardees who desperately need guidance but lack trusted, data-driven advisors.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.